Posts

Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines

Authors: Margherita Luongo, Oliviero Marinelli, Laura Zeppa, Cristina Aguzzi, Maria Beatrice Morelli, Consuelo Amantini, Andrea Frassineti, Marianne di Costanzo, Alessandro Fanelli, Giorgio Santoni, Massimo Nabissi Published in Cancers September 2020 Abstract Pancreatic cancer (PC) is related to lifestyle risks, chronic inflammation, and germline mutations in BRCA1/2, ATM, MLH1, TP53, or CDKN2A. Surgical resection and adjuvant…

Cannabis: An Emerging Treatment for Common Symptoms in Older Adults

Authors: Kevin H Yang, Christopher N Kaufmann, Reva Nafsu, Ella T Lifset, Khai Nguyen, Michelle Sexton, Benjamin H Han, Arum Kim, Alison A Moore Published in Journal of the American Geriatrics Society October 2020 Abstract Background/objectives: Use of cannabis is increasing in a variety of populations in the United States; however, few investigations about how…

Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation

Authors: Ester Pagano, Fabio A. Iannotti, Fabiana Piscitelli, Barbara Romano, Giuseppe Lucariello, Tommaso Venneri, Vincenzo Di Marzo, Angelo A. Izzo, Francesca Borrelli Published in Phytotherapy Research September 2020 Abstract Summary Fish oil (FO) and phytocannabinoids have received considerable attention for their intestinal anti‐inflammatory effects. We investigated whether the combination of FO with cannabigerol (CBG) and…

Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol

Authors: Maximus Berger, Emily Li, Günter Paul Amminger Published in BMJ Case Reports CP 2020 Abstract Anxiety disorders in young people are frequently comorbid with other mental disorders and respond unsatisfactorily to first-line treatment in many cases. Here, we report the case of a 20-year-old man with severe social anxiety disorder, major depressive disorder, insomnia…

Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy

Authors: Mathieu Kuchenbuch, Gianluca D’Onofrio, Nicole Chemaly, Giulia Barcia, Théo Teng, Rima Nabbout Published in Epilepsia Open July 2020 Abstract Mutations in SYNGAP1 are associated with developmental delay, epilepsy, and autism spectrum disorder (ASD). Epilepsy is often drug-resistant in this syndrome with frequent drop attacks. In a prospective study of add-on cannabidiol (CBD), we identified…

Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA

Authors: Hesam Khodadadi, Évila Lopes Salles, Abbas Jarrahi, Fairouz Chibane, Vincenzo Costigliola, Jack C Yu, Kumar Vaibhav, David C Hess, Krishnan M Dhandapani, Babak Baban Published in Cannabis and Cannabinoid Research September 2020 Abstract Introduction In the absence of effective antivirals and vaccination, the pandemic of COVID-19 remains the most significant challenge to our health…

Delegitimizing Cannabis Because of Its Recreational Use is the Real Lie

Sherry Yafai, MD encourages the need for healthcare professionals to shift their perspective on cannabis in her column for Emergency Medicine News. “Delegitimizing medications based simply on their potential for recreational use or abuse is a dangerous and uninformed approach for physicians.”

Cannabidiol in conjunction with clobazam: analysis of four randomized‐controlled trials

Authors: Boudewijn Gunning, Maria Mazurkiewicz‐Beldzinska, Richard F.M. Chin, Hari Bhathal Charlotte Nortvedt, Eduardo Dunayevich, Daniel Checketts Published in Acta Neurologica Scandinavica September 2020 Abstract Objectives To assess the efficacy and safety profile of add‐on cannabidiol (CBD) in patients with Lennox‐Gastaut syndrome (LGS) and Dravet syndrome (DS) on clobazam and in the overall population of four…

A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report

Authors: Juliana Andrea Ponton, Kim Smyth, Elias Soumbasis, Sergio Andres Llanos, Mark Lewis, Wilhelm August Meerholz & Robert Lawrence Tanguay Published in Journal of Medical Case Reports September 2020 Abstract   Background The pharmacological treatment for autism spectrum disorders is often poorly tolerated and has traditionally targeted associated conditions, with limited benefit for the core…

Perceptions and recommendation behaviors of dermatologists for medical cannabis: A pilot survey

Authors: Samuel Yeroushalmi, Kamaria Nelsona, Andrew Sparks, Adam Friedman Published in Complementary Therapies in Medicine September 2020 Abstract Objectives Evidence suggests that cannabinoids may provide therapeutic benefit to patients with dermatologic conditions. The recommendation behaviors of dermatologists with regards to recommending medical cannabis are unknown. We administered a pilot survey to evaluate dermatologists’ recommendation behaviors…

A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men

Authors: Hriday P. Bhambhvani BS, Alex M.Kasman MD, Genester Wilson-King MD, Michael L. Eisenberg MD Published in Sexual Medicine September 2020 Abstract Introduction Cannabis is the most commonly used drug in the United States; however, the effects of cannabis use on male sexual function are poorly understood. Aim To characterize the contemporary landscape of cannabis…

A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol

Authors: Falone Sunda, Afolake Arowolo Published in The FASEB Journal April 2020 Abstract Cannabidiol (CBD) is considered a non-psychoactive, antioxidant, and anti-inflammatory compound derived from the Cannabis sativa plant. There are various reports on the versatile function of CBD, including ameliorating chronic inflammation and fibrosis formation in several tissue types. However, only a hand full…